17 research outputs found
Two-stage optimal dispatching model and benefit allocation strategy for hydrogen energy storage system-carbon capture and utilization system-based micro-energy grid
To fully utilize the abundant renewable energy resources in county-level areas of China, this paper designs a novel structure of micro-energy grid integrating hydrogen energy storage (HES) system and carbon capture and utilization (CCU) system (HES-CCU-based MEG). And a carbon emission-green certificate equivalent interaction mechanism is established. Then, a two-stage optimal dispatching framework is proposed for mitigating the impact of uncertainty variables, including a day-ahead robust dispatching model and a real-time rolling optimization model. Thirdly, an entropy-Shapley-based benefit allocation method is constructed to allocate the benefits in dimensions of energy conservation, carbon emission reduction, and renewable power consumption among various devices. Finally, a micro-energy grid in Henan province, China, is selected as an example for case study. The results show that: (1) HES could transfer surplus renewable power and low-priced power to periods with high power prices, while CCU could achieves the cycle and utilization of CO2, leading to a decrease in power purchase costs and carbon emissions by 7.85% and 0.47%, respectively. (2) The two-stage optimal dispatching model gives full play to the flexibility adjustment ability of each device, mitigates the deviations caused by uncertainty variables, and formulates the optimal dispatching strategy. (3) The entropy-Shapley-based benefit allocation method could evaluate the contributions of each device in different dimensions, effectively, ensuring the rationality of benefit allocation results. Overall, the proposed model and method could utilize renewable energy resources in county-level areas, which is better to promote the clean and low-carbon transformation of the overall energy structure
Recommended from our members
Phase 2 Multicenter Trial of Rabbit Anti-Thymocyte Serotherapy In Myelodysplastic Syndrome: Rate of Hematological Improvement Associated with Pre-Treatment Disease Duration
Abstract
Abstract 602
Introduction:
T–cell depleting regimens that contain anti-thymocyte globulin (ATG) have been used for the treatment of myelodysplastic syndrome (MDS) suggesting a link between immune dysregulation and ineffective hematopoiesis in a subset of patients. Pre-treatment clinical features such as younger age, shorter duration of red cell transfusion dependence, and HLADR15 genotype were identified as response co-variates in a single institutional experience with equine ATG (eATG). We report results from the first US multicenter study examining rabbit (rATG) for the treatment of MDS.
Methods and Patients:
This study was a non-randomized, multicenter Phase II clinical trial of rATG (Thymoglobulin®) designed to examine the response and safety of this agent in MDS patients. The primary endpoint was IWG 2000 response rate with secondary analyses of duration of response, time to response, time to progression and tolerance. rATG 2.5 mg/kg/day was administered IV for 4 doses. The relationship between response and variables such as age, bone marrow cellularity, HLA-DR15, karyotype, blood counts, and disease duration were also investigated. Eligible patients had severe neutropenia (ANC < 1000), severe anemia (untransfused hemoglobin <9 g/dl), anemia requiring transfusion, or thrombocytopenia (platelet count < 50,000/mm3) plus the presence of 10% bone marrow blasts in patients with int-2. Patients with chronic myelomonocytic leukemia (CMML) and lab abnormalities were excluded. Statistical methods include Wilcoxon rank-sum test, Kaplan-Meier survival curve and log-rank test.
Results:
Between Aug.2004 and May 2010, 39 MDS patients were enrolled: 24 patients were eligible for treatment, and 21 evaluable for response. Drop out occurred due to initiation of therapy off study (n=5), non-compliance (n=1), death prior to treatment (n=2), and failure to meet eligibility criteria (n=7). IPSS risk categories in the evaluable patients included low-risk (n=6, 29%), int-1 (n=12, 57%), and int-2 (n=3, 14%). Infusion-related reactions were the most common adverse event, generally occurring with the first dose of rATG. There were 3 deaths among treated patients related to infection, including 1 patient with neutrophil hematologic improvement (HIN). Nine (43%) of the 21 evaluable patients experienced HI. Twelve (57%) were non-responsive including patients with stable disease (n=7, 33%) and disease progression (n=5, 24%) including 3 with excess blasts (n=2) or prior history of cancer treatment (n=1). The median time to response was 75 days (range 3 days–3.7 months) and median duration of response was 7.2 months (range 2–22+ months) with a median follow up of 20 months. Two patients maintained HI at the time of this analysis and response was extended in two patients by initiating cyclosporine As shown in Fig. 1, progression free survival (PFS) was greater in responders compared to non-responders (median PFS in responders 1 vs 0.23 year), but did not reach statistical significance (p=0.1). The mean age at treatment for evaluable patients was 64 years (median 66, range 44–79), however, age was not a significant co-variate for HI (median age in responders 65 years, non-responders 66, p=0.5). Only 4 patients had the HLADR15 allele, among whom 3 achieved HI (75%). Other factors such as IPSS, cytopenias, LDH, karyotype, age-adjusted bone marrow cellularity, and M:E ratio showed no association with HI in univariant analyses. Responding patients had a shorter time from diagnosis to treatment (responders median 8 months vs non-responders median 41.8 months, (p=0.18).
Conclusions:
This multicenter study provides evidence that rATG is safe and has significant activity in MDS that warrants further study. Although independent of age, a pretreatment rATG response algorithm inclusive of HLADR15 and duration of disease appears to be similar to prior predictive models of eATG response. These results suggest that T-cell depleting rATG therapy may produce the best clinical outcome when implemented early in the disease process and further suggests that T-cell hematological suppression may contribute to the initiation of MDS pathogenesis.
Support:
This trial was conducted by the Bone Marrow Failure-Rare Disease Clinical Research Network (BMF-RDCRN 5406) sponsored by the NIH and Genzyme, Corp. This trial was registered at www.clinicaltrials.gov (NCT00466843).
Disclosures:
Epling-Burnette: Genzyme: Consultancy, Research Funding. Maciejewski:Genzyme Corp: Research Funding